HER2 Support Group Forums - View Single Post - responses of herceptin with various inhibitors

fullofbeans · 11-07-2011, 05:45 PM

Good summary of the response rates of various combinations for anti Her:

http://www.nature.com/nrc/journal/v9...rc2656_T3.html

And a very good full article:

http://www.nature.com/nrc/journal/v9...l/nrc2656.html
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

José Baselga1 & Sandra M. Swain2 About the authors
Top of pageAbstract

Aberrant receptor expression or functioning of the epidermal growth factor receptor (Erbb) family plays a crucial part in the development and evolution of cancer. Inhibiting the signalling activity of individual receptors in this family has advanced the treatment of a range of human cancers. In this Review we re-evaluate the role of two important family members, ERBB2 (also known as HER2) and ERBB3 (also known as HER3), and explore the mechanisms of action and preclinical and clinical data for new therapies that target signalling through these pivotal receptors. These new therapies include tyrosine kinase inhibitors, antibody–chemotherapy conjugates, heat-shock protein inhibitors and antibodies that interfere with the formation of ERBB2–ERBB3 dimers.

We want the magic combo to be discovered.

11-07-2011, 05:45 PM	#1
fullofbeans Senior Member Join Date: Jan 2007 Location: UK Posts: 617	responses of herceptin with various inhibitors Good summary of the response rates of various combinations for anti Her: http://www.nature.com/nrc/journal/v9...rc2656_T3.html And a very good full article: http://www.nature.com/nrc/journal/v9...l/nrc2656.html Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 José Baselga1 & Sandra M. Swain2 About the authors Top of pageAbstract Aberrant receptor expression or functioning of the epidermal growth factor receptor (Erbb) family plays a crucial part in the development and evolution of cancer. Inhibiting the signalling activity of individual receptors in this family has advanced the treatment of a range of human cancers. In this Review we re-evaluate the role of two important family members, ERBB2 (also known as HER2) and ERBB3 (also known as HER3), and explore the mechanisms of action and preclinical and clinical data for new therapies that target signalling through these pivotal receptors. These new therapies include tyrosine kinase inhibitors, antibody–chemotherapy conjugates, heat-shock protein inhibitors and antibodies that interfere with the formation of ERBB2–ERBB3 dimers. We want the magic combo to be discovered. __________________ 35 y/o June 06: BC stage I Grade 3; ER/PR neg Her-2+++; lumpectomies Aug 06: Stage IV liver mets: 6 tumours July 06 to Jan 07: 2FEC+6Taxotere; 3TACE; LITT March 07- Sept 07: Vaccination trial (phase 2, peptide based) at the UW (Seattle). Herceptin since 2006 NED til Oct 09 Recurrence Oct 2009: to internal mammary gland since October 2009 missed on Oct and March 2010 scan.. palpable nodes in May 2010 when I realised.. Nov 2011:7 mets to lungs progressing fast failed hercp/tykerb/xeloda combo.. superior vena cava blocked: stent but face remains puffy April 2012: Teresa Trial, randomised to TDM1 Nov 2012 progressing on TDM1 Dec 2012 blockage of my airways by tumours, obliteration of these blocking tumours breathing better but hoping for more- at mo too many tumours to count in the lungs and nodes. Dec 2012 Starting new trial S-222611 phase 1b dual egfr her2+ inhibitor. 'Under no circumstances should you lose hope..' Dalai Lama Last edited by fullofbeans; 11-07-2011 at 05:50 PM..*